export const brainStem = [
  {
    id: 1,
    prompt:
      "Which of the following medications for MS works by reducing production of pro-inflammatory cytokines and increasing production of anti-inflammatory cytokines?",
    choices: ["Fingolimod", "Glatiramer acetate", "Ocrelizumab", "Nataluzumab"],
    correct: "Glatiramer acetate",
    tags: ["PD", "medium", "MoA", "MS", "Neurology"],
  },
  {
    id: 2,
    prompt:
      "Which of the following medications for MS can be taken orally and disrupts lymphocyte function by disrupting proliferation and inducing cytotoxicity/apoptosis of lymphocytes?",
    choices: ["Alemtuzumab", "Dimethyl fumarate", "Fingolimod", "Ocrelizumab"],
    correct: "Dimethyl fumarate",
    tags: ["PD", "medium", "MoA", "MS", "Neurology"],
  },
  {
    id: 3,
    prompt:
      "A 63 y/o male presents to the neurologist office after experiencing bouts of double vision and ataxia. These attacks have never happened before till recently. After a thorough diagnostic workup, he is diagnosed with primary progressive MS. Which of the following is the ONLY approved medication for primary progressive MS as of 2022?",
    choices: ["Alemtuzumab", "Fingolimod", "Interferons", "Natalizumab"],
    correct: "Natalizumab",
    tags: ["PD", "medium", "MoA", "MS", "Neurology"],
  },
  {
    id: 4,
    prompt:
      "A 64 y/o woman was recently diagnosed with Stage II ductal carcinoma in situ (DCIS). She undergoes a lumpectomy and further investigation reveals the tumor to be ER-, PR-, and HER2- (triple-negative). You need to pick a chemotherapeutic agent to be included in her adjuvant therapy. With your knowledge on the mechanisms of actions, which of the following drugs would be the most appropriate?",
    choices: [
      "Alemtuzumab",
      "Dimethyl fumarate",
      "Glatiramer acetate",
      "Ocrelizumab",
    ],
    correct: "Ocrelizumab",
    tags: ["PD", "medium", "MoA", "MS", "Neurology"],
  },
  {
    id: 5,
    prompt:
      "A 42 y/o patient with relapsing remitting MS has been experiencing increasingly more severe attacks. He is currently on dimethyl fumarate, but this has been ineffective at slowing down his progression. Which of the following medications with a similar mechanism of action would you prescribe him next?",
    choices: [
      "Alemtuzumab",
      "Cladribine",
      "Glatiramer acetate",
      "Nataluzumab",
      "Teriflunomide",
    ],
    correct: "Alemtuzumab",
    tags: ["PD", "medium", "MoA", "MS", "Neurology"],
  },
  {
    id: 6,
    prompt:
      "A 66 y/o patient with relapsing-remitting MS presents with progressively worsening attacks and symptom severity. His neurologist decides that the patientâ€™s cladribine is not an adequate treatment anymore. His neurologist decides to use a stronger drug, Drug X, but first orders a serology test for John Cunningham Virus (JCV) to assess the risk of progressive multifocal leukoencephalopathy (PML). What is the identity of drug X?",
    choices: ["Alemtuzumab", "Interferons", "Natalizumab", "Ocrelizumab"],
    correct: "Natalizumab",
    tags: ["PD", "medium", "MoA", "MS", "Neurology", "side effects"],
  },
];
